Technical Validation and Prospective Clinical Utility of Optical Genome Mapping in Acute Leukemia Workup: Insights from 200 Cases following Deployment as a First-Line Diagnostic Test in a Tertiary Care Center (IMAGE)
Caption
A study in The Journal of Molecular Diagnostics assessing the efficacy of optical genome mapping (OGM) in a cohort of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. This image shows that OGM provided added clinical value compared with standard-of-care testing in adult acute leukemia by identifying clinically significant genetic abnormalities in cases initially reported as normal or where standard testing failed. These additional findings led to meaningful changes in the diagnoses and/or risk assessments for nearly 20% of individuals with acute leukemia seen at the investigators’ tertiary care center.
Credit
The Journal of Molecular Diagnostics / Parlow et al.)
Usage Restrictions
Please include attribution.
License
Original content